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are not receiving appropriate follow-up care. The cause
of these low screening rates should be examined in future
research.
PCV8
CLINICAL AND ECONOMIC IMPACTS OF
PHARMACIST-MANAGED ANTICOAGULATION
MONITORING SERVICES
Doan QD1, Godley PJ2, Shepherd MD1, Lawson KA1,
Wilson JP1
1University of Texas at Austin, Austin,TX, USA; 2Scott & White
Memorial Hospital,Temple,TX, USA
OBJECTIVE: This study evaluated the effects of 
pharmacist-managed anticoagulation monitoring services
on the clinical and economic outcomes of patients pre-
scribed warfarin therapy. 
METHODS: A retrospective chart review was conducted
for patients newly initiated with warfarin therapy
between November 1997 and April 1998. Patients used
warfarin for a minimum of 2 months and were followed
for either one-year post-initiation of warfarin usage or
until discontinuation of warfarin therapy, whichever was
earlier. Comparisons were made between the group of
patients receiving anticoagulation monitoring through
usual medical care (UMC) by their physician (“UMC
group”) and those patients enrolled in the pharmacist-
managed anticoagulation clinic (“AC patients”).
Outcome measures for the two groups include anticoag-
ulation control, incidence of warfarin adverse effects or
recurrent thromboembolic disorder, and economic evalu-
ation for inpatient and outpatient health care services 
utilized.
RESULTS: Complete data for 63 UMC patients (625
patient-months) and 18 AC patients (232 patient-months)
indicate that AC patients had better anticoagulation
control than UMC patients (51% of INRs within target
range versus 41%, respectively). However, AC patients
experienced more frequent minor recurrences (events not
requiring hospitalization) of thromboembolic disorders
or bleeding associated with warfarin (0.11 events per 
AC patient-month versus 0.08 events per UMC patient-
month). The incidence of complications that necessitated
hospitalization was similar between the two groups. The
estimated annual inpatient cost of treating the complica-
tions associated with anticoagulant therapy was $168 less
per AC patient but equivalent for both groups for out-
patient services ($348 annually). Inpatient and outpatient
charges for all medical claims for AC patients were less
than half that found for UMC patients ($241 and $405
per patient-month versus $501 and $878 per patient-
month, respectively). 
CONCLUSION: Although treatment-related complica-
tions can still occur, pharmacist-managed anticoagulation
monitoring services provided a better means of main-
taining anticoagulation control and reducing medical care
costs for patients on warfarin therapy.
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OBJECTIVES: Type 2 diabetics with combined hyper-
lipidemia are at increased risk of developing coronary
heart disease (CHD). Fibrates have been shown to
improve lipid parameters; thereby, decreasing CHD risk
among treated patients. We compare fenoﬁbrate to gem-
ﬁbrozil treatment of combined hyperlipidemia in type 2
diabetics by determining the following: one year absolute
and relative risk reductions in CHD, Number Needed to
Treat (NNT) to prevent one case of CHD, and number
of CHD cases prevented. 
METHODS: In patients with lipid parameters consistent
with type 2 diabetes, absolute risk (AR) of developing
CHD in one year was determined using the Anderson car-
diovascular risk equation. Relative risk (RR) comparing
no treatment to treatment and NNT were calculated. 
The number of CHD cases prevented in one year was 
calculated from NNT and prevalence characteristics of 
a 500,000 member Medicaid population. Sensitivity
analyses were performed on age, smoking status, drug
dose, and time horizon.
RESULTS: Base case patients (60 year-old female, non-
smoker) treated with fenoﬁbrate (AR = 1.1, RR = 1.92,
NNT = 97) had lower absolute risks, more favorable 
relative risks comparing no treatment to treatment, and
required treatment of fewer patients to prevent one case
of CHD compared to gemﬁbrozil (AR = 1.5, RR = 1.42,
NNT = 157). In one year, in patients >50 years, 91 CHD
cases were prevented through the model with fenoﬁbrate
treatment, compared to 56 cases prevented with gemﬁ-
brozil. Each sensitivity analysis showed fenoﬁbrate had
the more favorable AR, RR, and NNT. For example,
using a ﬁve year time horizon on a 70 year-old smoking
male, fenoﬁbrate’s AR = 17.8, RR = 1.41, and NNT =
14, while with gemﬁbrozil’s AR = 21.0, RR = 1.20, 
and NNT = 24. In ﬁve years, 348 cases of CHD were 
prevented with fenoﬁbrate compared to 206 with 
gemﬁbrozil.
CONCLUSIONS: Fenoﬁbrate proves a better healthcare
value than gemﬁbrozil due to its superior risk reduction
and prevention of more cases of CHD.
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